Pharmacotherapy for bronchiectasis

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 18, 2007, Pages 3183-3193

  Loebinger, Michael R ^a   Wilson, Robert ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

bronchiectasis; infection; management; pharmacotherapy; pneumonia; treatment

Indexed keywords

ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; BRONCHODILATING AGENT;

BACTERIAL INFECTION; BRONCHIECTASIS; HUMAN; IMMUNOLOGY; MICROBIOLOGY; REVIEW;

ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; BACTERIAL INFECTIONS; BRONCHIECTASIS; BRONCHODILATOR AGENTS; HUMANS;

EID: 40949139408     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.8.18.3183     Document Type: Review

References (79)

1. BARKER AF: Bronchiectasis. N. Engl. J. Med. (2002) 346:1383-1393.
2. ROSEN MJ: Chronic cough due to bronchiectasis: ACCP evidence-based clinical practice guidelines. Chest (2006) 129:S122-S131.
3. WILSON R: Bronchiectasis. In: Respiratory Medicine (3rd Edition). Brewis RAL, Corrin B, Geddes DM, Gibson GJ (Eds), WB Saunders, London (2003): 1445-1464.
4. WILSON R, DOWLING RB, JACKSON AD: The biology of bacterial colonization and invasion of the respiratory mucosa. Eur. Respir. J. (1996) 9:1523-1530.
5. GAGA M, BENTLEYAM, HUMBERT M et al. : Increases in CD4+ T lymphocytes, macrophages, neutrophils and interleukin 8 positive cells in the airways of patients with bronchiectasis. Thorax (1998) 53:685-691.
6. SHUM DK, CHAN SC, IP MS: Neutrophil-mediated degradation of lung proteoglycans: stimulation by TNF-Ot in sputum of patients with bronchiectasis. Am. J. Respir. Crit. Care Med. (2000) 162:1925-1931.
7. COLE PJ: A new look at the pathogenesis and management of persistent bronchial sepsis: a vicious circle hypothesis and its logical therapeutic connatations. In: Strategies for the Management of Chronic Bronchial Sepsis . Davies RJ (Ed.), Medicine Publishing Foundation, Oxford (1984): 1-20.
8. PASTEUR MC, HELLIWELL SM, HOUGHTON SJ et al : An investigation into causative factors in patients with bronchiectasis. Am. J. Respir. Crit. Care Med. (2000) 162:1277-1284.
9. SHOEMARKA, OZEROVITCH L, WILSON R: Aetiology in adult patients with bronchiectasis. Respir. Med. (2007) 101(6): 1163-1170.
10. BUSSE PJ, RAZVI S, CUNNINGHAM-RUNDLES C: Effi cacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodefi ciency J. Allergy Clin. Immunol. (2002) 109:1001-1004.
11. QUARTIER P, DEBRE M, DE BLIC J et al. : Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: a retrospective survey of 31 patients. J. Pediatr. (1999) 134:589-596.
12. WARK PA, SALTOS N, SIMPSON J, SLATER S, HENSLEY MJ, GIBSON PG: Induced sputum eosinophils and neutrophils and bronchiectasis severity in allergic bronchopulmonary aspergillosis. Eur. Respir. J. (2000) 16:1095-1101.
13. WARK PA, GIBSON PG, WILSON AJ: Azoles for allergic bronchopulmonary aspergillosis associated with asthma. Cochrane Database Syst. Rev. (2004): CD001108.
14. STEVENS DA, SCHWARTZ HJ, LEE JY et al. : A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis. N. Engl. J. Med. (2000) 342:756-762.
15. WARK PA, HENSLEYMJ, SALTOS N et al.: Anti-infl ammatory effect of itraconazole in stable allergic bronchopulmonary aspergillosis: a randomized controlled trial. J. Allergy Clin. Immunol. (2003) 111:952-957.
16. GREER ND: Posaconazole (Noxafi l): a new triazole antifungal agent. Proc. (Bayl. Univ. Med. Cent.) (2007) 20:188-196.
17. JONES AP, WALLIS CE: Recombinant human deoxyribonuclease for cystic fi brosis. Cochrane Database Syst. Rev. (2003):CD001127.
18. WILLS PJ, WODEHOUSE T, CORKERY K, MALLON K, WILSON R, COLE PJ: Short-term recombinant human DNase in bronchiectasis. Effect on clinical state and in vitro sputum transportability. Am. J. Respir. Crit. Care Med. (1996) 154:413-417.
19. CROCKETT AJ, CRANSTON JM, LATIMER KM, ALPERS JH: Mucolytics for bronchiectasis. Cochrane Database Syst. Rev. (2001):CD001289.
20. O'DONNELL AE, BARKER AF, ILOWITE JS, FICK RB: Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase study group. Chest (1998) 113:1329-1334.
21. DAVISKAS E, ANDERSON SD, EBERL S, CHAN HK, BAUTOVICH G: Inhalation of dry powder mannitol improves clearance of mucus in patients with bronchiectasis. Am. J. Respir. Crit. Care Med. (1999) 159:1843-1848.
22. DAVISKAS E, ANDERSON SD, GOMES K et al. : Increase in health status after 12 days treatment with inhaled mannitol in patients with bronchiectasis. Eur. Resp. J. (2003) 22(Suppl. 33):S430.
23. FRANCO F, SHEIKH A, GREENSTONE M: Short acting β-2 agonists for bronchiectasis. Cochrane Database Syst. Rev. (2003):CD003572.
24. SHEIKH A, NOLAN D, GREENSTONE M: Long-acting β-2-agonists for bronchiectasis. Cochrane Database Syst. Rev. (2001):CD002155.
25. LASSERSON T, HOLT K, EVANS D, GREENSTONE M: Anticholinergic therapy for bronchiectasis. Cochrane Database Syst. Rev. (2001):CD002163.
26. STEELE K, GREENSTONE M, LASSERSON JA: Oral methyl-xanthines for bronchiectasis. Cochrane Database Syst. Rev. (2001):CD002734.
27. CORLESS JA, WARBURTON CJ: Leukotriene receptor antagonists for non-cystic fi brosis bronchiectasis. Cochrane Database Syst. Rev. (2000):CD002174.
28. CHANG C, SINGLETON R, MORRIS P, CHANG A: Pneumococcal vaccines for children and adults with bronchiectasis. Cochrane Database Syst. Rev. (2007):CD006316.
29. DAVIES G, WELLS AU, DOFFMAN S, WATANABE S, WILSON R: The effect of Pseudomonas aeruginosa on pulmonary function in patients with bronchiectasis. Eur. Respir. J. (2006) 5:974-979.
30. WILSON CB, JONES PW, O'LEARY CJ et al. : Effect of sputum bacteriology on the quality of life of patients with bronchiectasis. Eur. Respir. J. (1997) 10:1754-1760.
31. WILSON CB, JONES PW, O'LEARY CJ et al : Health status assessment in bronchiectasis using the St George's respiratory questionnaire. Am. J. Respir. Crit. Care Med. (1997) 156:536-541.
32. EVANS SA, TURNER SM, BOSCH BJ, HARDY CC, WOODHEAD MA: Lung function in bronchiectasis: the infl uence of Pseudomonas aeruginosa. Eur. Respir. J. (1996) 9:1601-1604.
33. WILSON CB, JONES PW, O'LEARY CJ et al. : Systemic markers of infl ammation in stable bronchiectasis. Eur. Respir. J. (1998) 12:820-824.
34. RAS G, WILSON R, TODD H, TAYLOR G, COLE P: Effect of bacterial products on neutrophil migration in vitro. Thorax (1990) 45:276-280.
35. HILL AT, CAMPBELL EJ, HILL SL, BAYLEY DL, STOCKLEY RA: Association between airway bacterial load and markers of airway infl ammation in patients with stable chronic bronchitis. Am. J. Med. (2000) 109(4):288-295.
36. CURRIE DC, HIGGS E, METCALFE S, ROBERTS DE, COLE PJ: Simple method of monitoring colonising microbial load in chronic bronchial sepsis: pilot comparison of reduction in colonising microbial load with antibiotics given intermittently and continuously. J. Clin. Pathol. (1987) 40:830-836.
37. STOCKLEY RA, HILL SL, MORRISON HM: Effect of antibiotic treatment on sputum elastase in bronchiectatic outpatients in a stable clinical state. Thorax (1984) 39:414-419.
38. DROBNIC ME, SUNE P, MONTORO JB, FERRER A, ORRIOLS R: Inhaled tobramycin in non-cystic fi brosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa. Ann. Pharmacother. (2005) 39:39-44.
39. ORRIOLS R, ROIG J, FERRER J et al.: Inhaled antibiotic therapy in non-cystic fi brosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa. Respir. Med. (1999) 93:476-480.
40. CYMBALAAA, EDMONDS LC, BAUER MA et al.: The disease-modifying effects of twice-weekly oral azithromycin in patients with bronchiectasis. Treat. Respir. Med. (2005) 4:117-122.
41. BARKERAF, COUCH L, FIEL SB et al.: Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am. J. Respir. Crit Care Med. (2000) 162:481-485.
42. CURRIE DC, GARBETT ND, CHAN KL et al.: Double-blind randomized study of prolonged higher-dose oral amoxycillin in purulent bronchiectasis. Q. J. Med. (1990) 76:799-816.
43. KOH YY, LEE MH, SUN YH, SUNG KW, CHAE JH: Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double-blind, placebo-controlled study. Eur. Respir. J. (1997) 10:994-999.
44. YALCIN E, KIPERN, OZCELIKU et al.: Effects of claritromycin on infl ammatory parameters and clinical conditions in children with bronchiectasis. J. Clin. Pharm. Ther. (2006) 31:49-55.
45. EVANS D, BARA A, GREENSTONE M: Prolonged antibiotics for purulent bronchiectasis in children and adults. Cochrane Database Syst. Rev. (2007):CD001392.
46. HODSON ME, GALLAGHER CG: New clinical evidence from the European tobramycin trial in cystic fi brosis. J. Cyst. Fibros. (2002) 1:199-202.
47. HODSON ME, GALLAGHER CG, GOVAN JR: A randomised clinical trial of nebulised tobramycin or colistin in cystic fi brosis. Eur. Respir. J. (2002) 20:658-664.
48. SZAFF M, HOIBYN, FLENSBORG EW Frequent antibiotic therapy improves survival of cystic fi brosis patients with chronic Pseudomonas aeruginosa infection. Acta Paediatr. Scand. (1983) 72:651-657.
49. NGUYEN M, CHUNG EP: Telithromycin: the fi rst ketolide antimicrobial. Clin. Ther. (2005) 27:1144-1163.
50. JOHNSTON SL: Macrolide antibiotics and asthma treatment. J. Allergy Clin. Immunol. (2006) 117:1233-1236.
51. JOHNSTON SL, BLASI F, BLACK PN, MARTIN RJ, FARRELL DJ, NIEMAN RB: The effect of telithromycin in acute exacerbations of asthma. N. Engl. J. Med. (2006) 354:1589-1600.
52. MIRAVITLLES M, MOLINA J, BROSA M: Clinical effi cacy of moxifl oxacin in the treatment of exacerbations of chronic bronchitis: a systematic review and meta-analysis. Arch. Bronconeumol. (2007) 43:22-28.
53. WILSON R, KUBIN R, BALLIN I et al.: Five day moxifl oxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis. J. Antimicrob. Chemother (1999) 44:501-513.
54. WILSON R, ALLEGRA L, HUCHON G et al. : Short-term and long-term outcomes of moxifl oxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. Chest (2004) 125:953-964.
55. PENNINGTON JE: Hospital-acquired pneumonia. In: Respiratory Infections: Diagnosis and Management, (3rd Edition). Pennington JE (Ed.), Raven Press, NewYork (1994):207-227.
56. KOLBE J, WELLS A, RAM FS: Inhaled steroids for bronchiectasis. Cochrane Database Syst. Rev. (2000):CD000996.
57. TSANG KW, HO PI, CHAN KN et al: A pilot study of low-dose erythromycin in bronchiectasis. Eur. Respir. J. (1999) 13:361-364.
58. TSANG KW, TAN KC, HO PL et al: Inhaled fl uticasone in bronchiectasis: a 12 month study. Thorax (2005) 60(3):239-243.
59. KONSTAN MW, BYARD PJ, HOPPEL CL, DAVIS PB: Effect of high-dose ibuprofen in patients with cystic fi brosis. N. Engl. J. Med. (1995) 332:848-854.
60. KAPUR N, CHANG AB: Oral non steroid anti-infl ammatories for bronchiectasis in children and adults (Protocol). Cochrane Database Syst. Rev (2007):CD006427.
61. CHENG K, ASHBY D, SMYTH R: Oral steroids for cystic fi brosis. Cochrane Database Syst. Rev. (2000):CD000407.
62. AUERBACH HS, WILLIAMS M, KIRKPATRICK JA, COLTEN HR: Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fi brosis. Lancet (1985) 2:686-688.
63. EIGEN H, ROSENSTEIN BJ, FITZSIMMONS S, SCHIDLOW DV: A multicenter study of alternate-day prednisone therapy in patients with cystic fi brosis. Cystic fi brosis foundation prednisone trial group. J. Pediatr. (1995) 126:515-523.
64. LASSERSON T, HOLT K, GREENSTONE M: Oral steroids for bronchiectasis (stable and acute exacerbations). Cochrane Database Syst. Rev. (2001):CD002162.
65. KUDOH S, UETAKET, HAGIWARA K et al. : Clinical effects of low-dose long-term erythromycin chemotherapy on diffuse panbronchiolitis. Nihon Kyobu Shikkan Gakkai Zasshi (1987) 25:632-642.
66. RICHELDI L, FERRARA G, FABBRI LM, LASSERSON TJ, GIBSON PG: Macrolides for chronic asthma. Cochrane Database Syst. Rev. (2005):CD002997.
67. PARNHAM MJ, CULIC O, ERAKOVIC V et al. : Modulation of neutrophil and infl ammation markers in chronic obstructive pulmonary disease by short-term azithromycin treatment. Eur. J. Pharmacol. (2005) 517:132-143.
68. IVETIC TV, BOSNJAK B, HRVACIC B et al.: Anti-infl ammatory activity of azithromycin attenuates the effects of lipopolysaccharide administration in mice. Eur. J. Pharmacol. (2006) 539:131-138.
69. ANDERSON R: Erythromycin and roxithromycin potentiate human neutrophil locomotion in vitro by inhibition of leukoattractant-activated superoxide generation and autooxidation. J. Infect. Dis. (1989) 159:966-973.
70. SCHULTZ MJ, SPEELMAN P, ZAAT S, VAN DEVENTER SJ, VAN DER PT: Erythromycin inhibits TNF-α and interleukin 6 production induced by heat-killed Streptococcus pneumoniae in whole blood. Antimicrob. Agents Chemothe (1998) 42:1605-1609.
71. NAKAMURA H, FUJISHIMA S, INOUE T et al. : Clinical and immunoregulatory effects of roxithromycin therapy for chronic respiratory tract infection. Eur. Respir. J. (1999) 13:1371-1379.
72. GOSWAMI SK, KIVITY S, MAROM Z: Erythromycin inhibits respiratory glycoconjugate secretion from human airways in vitro Am. Rev. Respir. Dis. (1990) 141:72-78.
73. TAMAOKI J, ISONO K, SAKAI N, KANEMURA T, KONNO K: Erythromycin inhibits Cl secretion across canine tracheal epithelial cells. Eur. Respir. J. (1992) 5:234-238.
74. DAVIES G, WILSON R: Prophylactic antibiotic treatment of bronchiectasis with azithromycin. Thorax (2004) 59:540-541.
75. DALHOFF A: Immunomodulatory activities of fl uoroquinolones. Infection (2005) 33(Suppl. 2):55-70.
76. DOWLING RB, JOHNSON M, COLE PJ, WILSON R: The effect of rolipram, a type IV phosphodiesterase inhibitor, on Pseudomonas aeruginosa infection of respiratory mucosa. J. Pharmacol. Exp. Ther. (1997) 282(3):1565-1571.
77. AGASTHIANT, DESCHAMPS C, TRASTEK VF, ALLEN MS, PAIROLERO PC: Surgical management of bronchiectasis. Ann. Thorac. Surg. (1996) 62:976-978.
78. BALKANLI K, GENC O, DAKAK M et al. : Surgical management of bronchiectasis: analysis and short-term results in 238 patients. Eur. J. Cardiothorac. Surg. (2003) 24:699-702.
79. ARCASOY SM, KOTLOFF RM: Lung transplantation. N. Engl. J. Med. (1999) 340(14):1081-1091.